Publikationsübersicht

Wissenschaftliche Originalarbeiten in referierten Zeitschriften (Peer Review)
Anzahl Publikationen 326
davon Erstautorschaften 34
davon Seniorautorschaften 87
Buchbeiträge 33
Persönlicher h-index
42 Kumulativer Impact Factor IF 482.365
Zitationen gesamt 7400 (Google Scholar)

 

Verzeichnis der wichtigsten Publikationen (64 mit Impact Factor > IF 3.0)
Wissenschaftliche Originalarbeiten in referierten Zeitschriften (Peer Review)

Bonzheim I, Giese S, Deuter C, Süsskind D, Zierhut M, Waizel M, Szurman P, Federmann B, Schmidt J, Quintanilla-Martinez L, Coupland SE, Bartz-Schmidt KU. Fend F. High frequency of MYD88 mutations in vitreoretinal B-cell lymphoma: a valuable tool to improve diagnostic yield of vitreous aspirates. Blood 2015; 126: 76-79 [IF 10.452]
Schaffrath K, Schellhase H, Walter P, Augustin A, Chizzolini M, Kirchhof B, Grisanti S, Wiedemann P, Szurman P, Richard G, Greenberg RJ, Dorn JD, Parmeggiani F, Rizzo S. One-Year Safety and Performance Assessment of the Argus II Retinal Prosthesis: A Postapproval Study. JAMA Ophthalmol. 2019; 137: 896-902 [IF 6.198]
Zrenner E, Bartz-Schmidt KU, Benav H, Besch D, Bruckmann A, Gabel VP, Gekeler F, Greppmaier U, Harscher A, Kibbel S, Koch J, Kusnyerik A, Peters T, Stingl K, Sachs H, Stett A, Szurman P, Wilhelm B, Wilke R. Subretinal electronic chips allow blind patients to read letters and combine them to words. Proc Biol Sci 2011; 278: 1489-1497 [IF 5.683]
Zhu Q, Ziemssen F, Henke-Fahle S, Tatar O, Szurman P, Aisenbrey S, Schneiderhan-Marra N, Xu X, Grisanti S. Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization. Ophthalmology 2008; 115; 1750-1755 [IF 5.296]
Tatar O, Adam A, Shinoda K, Kaiserling E, Boeyden V, Claes C, Eckardt C, Eckert T, Pertile G, Scharioth GB, Yoeruek E, Szurman P, Bartz-Schmidt KU, Grisanti S. Early effects of intravitreal triamcinolone acetonide on inflammation and proliferation in human choroidal neovascularization. Arch Ophthalmol 2009; 127: 275-281 [IF 3.859]
Spitzer MS, Yoeruek E, Leitritz MA, Szurman P, Bartz-Schmidt KU. A new technique for treating posttraumatic aniridia with aphakia: first results of haptic fixation of a foldable intraocular lens on a foldable and custom-tailored iris prosthesis. Arch Ophthalmol 2012; 130: 771-775 [IF 3.859]
Ebner M, Mariacher S, Januschowski K, Boden K, Seuthe AM, Szurman P, Boden KT. Comparison of intraocular pressure during the application of a liquid patient interface (FEMTO LDV Z8) for femtosecond laser-assisted cataract surgery using two different vacuum levels. Br J Ophthalmol 2017; 101: 1138-1142 [IF 3.806]
Paul C, Heun C, Müller HH, Hoerauf H, Feltgen N, Wachtlin J, Kaymak H, Mennel S, Koss MJ, Fauser S, Maier MM, Schumann RG, Mueller S, Chang P, Schmitz-Valckenberg S, Kazerounian S, Szurman P, Lommatzsch A, Bertelmann T. Calculating the individual probability of successful ocriplasmin treatment in eyes with VMT syndrome: a multivariable prediction model from the EXPORT study. Br J Ophthalmol 2018; 102: 1092-1097 [IF 3.806]
Szurman P, Roters S, Grisanti S, Aisenbrey S, Schraermeyer U, Lüke M, Bartz-Schmidt KU, Thumann G. Ultrastructural changes following artificial retinal detachment with modified retinal adhesion. Invest Ophthalmol Vis Sci 2006; 47: 4983-4989 [IF 3.766] Szurman P, Roters S, Grisanti S, Aisenbrey S, Schraermeyer U, Lüke M, Bartz-Schmidt KU, Thumann G. Ultrastructural changes following artificial retinal detachment with modified retinal adhesion. Invest Ophthalmol Vis Sci 2006; 47: 4983-4989 [IF 3.766]
P. Szurman, K. Boden, K. Januschowski. Suprachoroidal hydrogel buckle as surgical treatment of retinal detachments – biocompatibility and first experiences. Retina 2016; 36: 1786-1790 [IF 3.700]
Al-Nawaiseh S, Rickmann A, Seuthe AM, Al-Rimawi D, Stanzel BV, Szurman P. A revised predictive biomarker for ocriplasmin therapy in vitreomacular traction disorders. Retina 2021; Epub ahead of print. PMID: 34173361 [IF 3.649]
Januschowski K, Boden KT, Macek AM, Szurman P, Bisorca-Gassendorf L, Hoogmartens C, Rickmann A. A modified sutureless intrascleral fixation technique for secondary intraocular lens implantation - a pilot study. Retina 2021; Epub ahead of print. PMID: 34050099 [IF 3.649]
Grisanti S, Szurman P, Warga M, Kaczmarek R, Ziemssen F, Tatar O, Bartz-Schmidt KU. Decorin modulates wound healing in experimental glaucoma filtration surgery: a pilot study. Invest Ophthalmol Vis Sci 2005; 46: 191-196 [IF 3.643] Rizzo S, Barale PO, Ayello-Scheer S, Devenyi RG, Delyfer MN, Korobelnik JF, Rachitskaya A, Yuan A, Jayasundera KT, Zacks DN, Handa JT, Montezuma SR, Koozekanani D, Stanga PE, da Cruz L, Walter P, Augustin AJ, Chizzolini M, Olmos de Koo LC, Ho AC, Kirchhof B, Hahn P, Vajzovic L, Iezzi R Jr, Gaucher D, Arevalo JF, Gregori NZ, Grisanti S, Özmert E, Yoon YH, Kokame GT, Lim JI, Szurman P, de Juan E Jr, Rezende FA, Salzmann J, Richard G, Huang SS, Merlini F, Patel U, Cruz C, Greenberg RJ, Justus S, Cinelli L, Humayun MS. ADVERSE EVENTS OF THE ARGUS II RETINAL PROSTHESIS: Incidence, Causes, and Best Practices for Managing and Preventing Conjunctival Erosion. Retina 2020; 40: 303-311 [IF 3.649] Röhrig S, Farecki ML, Boden KT, Haus A, Gutfleisch M, Jung S, Lommatzsch A, Szurman P, Januschowski K. NEGATIVE EFFECTS OF VITAL DYES AFTER UNEVENTFUL VITREOMACULAR SURGERY. Retina 2019; 39: 1772-1778 [IF 3.649]
Schramm C, Spitzer MS, Henke-Fahle S, Steinmetz G, Januschowski K, Heiduschka P, Geis-Gerstorfer J, Biedermann T, Bartz-Schmidt KU, Szurman P. The cross-linked biopolymer hyaluronic acid as an artificial vitreous substitute. Invest Ophthalmol Vis Sci 2012; 53: 613-621 [IF 3.528]
Wilke R, Gabel VP, Sachs H, Bartz Schmidt KU, Gekeler F, Besch D, Szurman P, Stett A, Wilhelm B, Peters T, Harscher A, Greppmaier U, Kibbel S, Benav H, Bruckmann A, Stingl K, Kusnyerik A, Zrenner E. Spatial Resolution and Perception of Patterns Mediated by a Subretinal16-Electrode Array in Patients Blinded by Hereditary Retinal Dystrophies. Invest Ophthalmol Vis Sci 2011; 52: 5995-6003 [IF 3.582]
Spitzer MS, Kaczmarek RT, Yoeruek E, Petermeier K, Wong D, Heimann H, Jaissle GB, Bartz-Schmidt KU, Szurman P. The distribution, release kinetics and biocompatibility of triamcinolone injected and dispersed in silicone oil. Invest Ophthalmol Vis Sci 2009; 50: 2337-2343 [IF 3.582]
Grisanti S, Szurman P, Gelisken F, Aisenbrey S, Oficjalska-Mlynczak J, Bartz-Schmidt KU. Histological findings in experimental macular surgery with indocyanine green. Invest Ophthalmol Vis Sci 2004; 45: 282-286 [IF 3.577]
Heiduschka P, Fietz H, Hofmeister S, Schultheiss S, Mack AF, Peters S, Ziemssen F, Niggemann B, Julien S, Bartz-Schmidt KU, Schraermeyer U; Tübingen Bevacizumab Study Group. Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci 2007; 48: 2814-2823 [IF 3.577]
Yoeruek E, Spitzer MS, Tatar O, Biedermann T, Grisanti S, Lüke M, Bartz-Schmidt KU, Szurman P. Toxic effects of recombinant tissue plasminogen activator on human corneal endothelial cells. Invest Ophthalmol Vis Sci 2008; 49: 1392-1397 [IF 3.528] Spitzer MS, Kaczmarek RT, Yoeruek E, Petermeier K, Wong D, Heimann H, Jaissle GB, Bartz-Schmidt KU, Szurman P. The distribution, release kinetics and biocompatibility of triamcinolone injected and dispersed in silicone oil. Invest Ophthalmol Vis Sci 2009; 50: 2337-2343 [IF 3.528]
Schramm C, Spitzer MS, Henke-Fahle S, Steinmetz G, Januschowski K, Heiduschka P, Geis-Gerstorfer J, Biedermann T, Bartz-Schmidt KU, Szurman P. The cross-linked biopolymer hyaluronic acid as an artificial vitreous substitute. Invest Ophthalmol Vis Sci 2012; 53: 613-621 [IF 3.528]
Yoeruek E, Spitzer MS, Tatar O, Biedermann T, Lüke M, Bartz-Schmidt KU, Szurman P. Toxic effects of recombinant tissue plasminogen activator on human corneal endothelial cells. Invest Ophthalmol Vis Sci 2008; 49: 1392-1397 [IF 3.528]
Spitzer MS, Mlynczak T, Schultheiss M, Rinker K, Yoeruek E, Petermeier K, Januschowski K, Szurman P. Preservative-free triamcinolone acetonide injectable suspension versus "traditional" triamcinolone preparations: impact of aggregate size on retinal biocompatibility. Retina 2011; 31: 2050-2057 [IF 3.478] Peters S, Tatar O, Spitzer MS, Szurman P, Aisenbrey S, Lüke M, Adam A, Yoeruek E, Grisanti S. Analysis of the neuronal marker protein gene product 9.5 in internal limiting membranes after indocyanine-green assisted peeling. Retina 2009; 29: 243-247 [IF 3.478]
Jaissle GB, Ulmer A, Henke-Fahle S, Fierlbeck G, Bartz-Schmidt KU, Szurman P. Suppression of melanoma-associated neoangiogenesis by bevacizumab. Arch Dermatol 2008; 144: 525-527 [IF 3.402]
Schatz A, Seuthe AM, Januschowski K. Effect of Ocriplasmin on objectively assessed retinal function after treatment of vitreomacular diseases. Acta Ophthalmol 2019; 97: e700-e705 [IF 3.362]
Erokhina M, Szurman P, Dimopoulos S, Januschowski K, Seuthe AM. Postoperative cystoid macular oedema after non-penetrating glaucoma surgery. Acta Ophthalmol 2021. Epub ahead of print. PMID: 33538397 [IF 3.362]
Boden KT, Schlosser R, Reipen L, Seitz B, Januschowski K, Szurman P, Wakili P, Julich-Haertel H, Rickmann A. The impact of limbus detection, arcus lipoides and limbal vessels on the primary patency of clear cornea incisions in femtosecond laser-assisted cataract surgery. Acta Ophthalmol 2021; Epub ahead of print. PMID: 33502099 [IF 3.362]
Rickmann A, Boden KT, Trouvain AM, Wahl S, Schulz A, Thaler S, Szurman P. Single peripheral triangular mark ensuring correct graft orientation in DMEK. Acta Ophthalmol 2021; Epub ahead of print. PMID: 34145763 [IF 3.362] Gunnemann ML, Röhrig S, Gutfleisch M, Lommatzsch A, Szurman P, Boden K, Januschowski K. Frequency of retinal detachment after surgical treatment of full-thickness macular holes with 23-gauge pars plana vitrectomy. Acta Ophthalmol 2021; 99: e441-e442 [IF 3.362]
Schulz A, Rickmann A, Julich-Haertel H, Germann A, von Briesen H, Januschowski K, Szurman P. Comparative cytotoxic and antiproliferative profile of methotrexate and fluorouracil on different ocular cells. Acta Ophthalmol 2020; Epub ahead of print. PMID: 33381918 [IF 3.362]
Khanani AM, Constantine RN, Blot KH, Lescrauwaet B, Szurman P. Effectiveness of ocriplasmin in real-world settings: A systematic literature review, meta-analysis, and comparison with randomized trials. Acta Ophthalmol 2020; Epub ahead of print. PMID: 33369248 [IF 3.362]
Rickmann A, Wahl S, Katsen-Globa A, Schulz A, Pütz N, Szurman P. Cleavage plane after liquid-bubble preparation of Descemet's membrane. Acta Ophthalmol 2020; Epub ahead of print. PMID: 33354909 [IF 3.362]
Ilmarinen T, Thieltges F, Hongisto H, Juuti-Uusitalo K, Koistinen A, Kaarniranta K, Brinken R, Braun N, Holz FG, Skottman H, Stanzel BV. Survival and functionality of xeno-free human embryonic stem cell-derived retinal pigment epithelial cells on polyester substrate after transplantation in rabbits. Acta Ophthalmol 2019; 97: e688-e699 [IF 3.362]
Rickmann A, Boden KE, Wahl S, Jung S, Boden KT, Szurman P, Januschowski K. Significant differences between specular microscopy and corneal bank endothelial cell counts - a pilot study. Acta Ophthalmol. 2019; 97: e1077-e1081 [IF 3.362]
Mariacher S, Ebner M, Hurst J, Szurman P, Januschowski K. Implantation and testing of a novel episcleral pressure transducer: A new approach to telemetric intraocular pressure monitoring. Exp Eye Res. 2017; 166: 84-90 [IF 3.332]
Szurman P, Warga M, Roters S, Grisanti S, Heimann U, Aisenbrey S, Rohrbach JM, Sellhaus B, Ziemssen F, Bartz-Schmidt KU. Experimental implantation and long-term testing of an Intraocular Vision Aid in rabbits. Arch Ophthalmol 2005; 123: 964-969 [IF 3.274]
Tatar O, Shinoda K, Kaiserling E, Pertile G, Eckardt C, Mohr A, Yoeruek E, Szurman P, Bartz-Schmidt KU, Grisanti S. Early effects of triamcinolone acetonide on vascular endothelial growth factor and endostatin in human choroidal neovascularization. Arch Ophthalmol 2008; 126: 193-199 [IF 3.242]
Tatar O, Yoeruek E, Szurman P, Bartz-Schmidt KU; Tübingen Bevacizumab Study Group, Adam A, Shinoda K, Eckardt C, Boeyden V, Claes C, Pertile G, Scharioth GB, Grisanti S. Effect of bevacizumab on inflammation and proliferation in human choroidal neovascularization. Arch Ophthalmol 2008;126: 782-790 [IF 3.242]
Aisenbrey S, Lafaut BA, Szurman P, Hilgers R-D, Esser P, Walter P, Bartz-Schmidt KU, Thumann G. Iris pigment epithelial translocation in the treatment of exudative macular degeneration: A three-year follow-up. Arch Ophthalmol 2006; 124:183-188 [IF 3.206]
Szurman P, Warga M, Bartz-Schmidt KU. Correspondence: Reply to Liu DTL, Chi-Lai L, Lee VYW, Lam DSC. Experimental implantation and long-term testing of an Intraocular Vision Aid in rabbits. Arch Ophthalmol 2006; 124: 610 [IF 3.206]
Szurman P, Warga M, Roters S, Grisanti S, Heimann U, Aisenbrey S, Rohrbach JM, Sellhaus B, Ziemssen F, Bartz-Schmidt KU. Experimental implantation and long-term testing of an Intraocular Vision Aid in rabbits. Arch Ophthalmol 2005; 123: 964-969 [IF 3.274] Rickmann A, Paez LR, Della Volpe Waizel M, Bisorca-Gassendorf L, Schulz A, Vandebroek AC, Szurman P, Januschowski K. Functional and structural outcome after vitrectomy combined with subretinal rtPA Injection with or without additional intravitreal Bevacizumab injection for submacular hemorrhages. PLoS One 2021; 16: e0250587 [3.240]
Januschowski K, Schnichels S, Hurst J, Hohenadl C, Reither C, Rickmann A, Pohl L, Bartz-Schmidt KU, Spitzer MS. Ex vivo biophysical characterization of a hydrogel-based artificial vitreous substitute. PLoS One 2019, 14: e0209217 [IF 3.240] Schnichels S, Schneider N, Hohenadl C, Hurst J, Schatz A, Januschowski K, Spitzer MS. Efficacy of two different thiol-modified crosslinked hyaluronate formulations as vitreous replacement compared to silicone oil in a model ofretinal detachment. PLoS One 2017; 12: e0172895 [IF 3.240]
Rickmann A, Paez LR, Della Volpe Waizel M, Bisorca-Gassendorf L, Schulz A, Vandebroek AC, Szurman P, Januschowski K. Functional and structural outcome after vitrectomy combined with subretinal rtPA Injection with or without additional intravitreal Bevacizumab injection for submacular hemorrhages. PLoS One 2021; 16: e0250587 [IF 3.240]
Spitzer MS, Nessmann A, Wagner J, Yoeruek E, Bartz-Schmidt KU, Szurman P, Szurman GB. Customized humanoptics silicone iris prosthesis in eyes with posttraumatic iris loss: outcomes and complications. Acta Ophthalmol. 2016; 94: 301-306 [IF 3.157]
Seuthe AM, Januschowski K, Mariacher S, Ebner M, Opitz N, Szurman P, Boden K. The effect of canaloplasty with suprachoroidal drainage combined with cataract surgery - 1-year results. Acta Ophthalmol 2018; 96: e74-e78 [IF 3.157] Heider A, Dimopoulos S, Szurman P, Januschowski K. Real-life experience with intravitreal ocriplasmin on vitreomacular traction and full-thickness macular holes. Acta Ophthalmol 2018; 96: e890-891 [IF 3.153]
Szurman P, Roters S, Grisanti S, Aisenbrey S, Rohrbach JM, Warga M, Gelisken F, Spitzer MS, Bartz-Schmidt KU. Primary silicone oil endotamponade in the management of severe intraocular foreign body injuries: an eight-year follow-up. Retina 2007; 27: 304-311 [IF 3.088]
Szurman P, Roters S, Grisanti S, Aisenbrey S, Rohrbach JM, Warga M, Gelisken F, Spitzer MS, Bartz-Schmidt KU. Primary silicone oil endotamponade in the management of severe intraocular foreign body injuries: an eight-year follow-up. Retina 2007; 27: 304-311 [IF 3.088] Yoeruek E, Jaegle H, Lüke M, Grisanti S, Warga M, Krott R, Spitzer MS, Tatar O, Bartz-Schmidt KU, Szurman P. Safety profile of a taurine containing irrigation solution (AcriPurRet®) in pars plana vitrectomy. Retina 2007; 27: 1286-1291 [IF 3.088]
Tatar O, Adam A, Shinoda K, Yoeruek E, Szurman P, Bopp S, Eckardt C, Bartz-Schmidt KU, Grisanti S. Influence of Verteporfin Photodynamic Therapy on Inflammation in Human Choroidal Neovascular Membranes secondary to Age-Related Macular Degeneration. Retina 2007; 27: 713-723 [IF 3.088]
Veckeneer M, Mohr A, Alharthi E, Azad R, Bashshur ZF, Bertelli E, Bejjani RA, Bouassida B, Bourla D, Crespo IC, Fahed C, Fayyad F, Mura M, Nawrocki J, Rivett K, Scharioth GB, Shkvorchenko DO, Szurman P, Van Wijck H, Wong IY, Wong DS, Frank J, Oellerich S, Bruinsma M, Melles GR. Novel 'heavy' dyes for retinal membrane staining during macular surgery: multicenter clinical assessment. Acta Ophthalmol 2014; 92: 339-344 [IF 3.032]
Januschowski K, Dimopoulos S, Szurman P, Feltgen N, Spitzer B, Pielen A, Rehak M, Spital G; Bevacizumab Study Group Venous Occlusion, Meyer CH, Szurman GB. Injection scheme for intravitreal bevacizumab therapy for macular oedema due to central retinal vein occlusion: results of a multicenter study. Acta Ophthalmol 2015: 93: 400-402 [IF 3.032]
Kitiratschky V, Deuter C, Beck R, Schulte B, Müller H, Blumenstock G, Bartz-Schmidt KU, Szurman P. Relationship between suspected reasons of intraocular inflammation and the results of diagnostic vitrectomy: an observational study. Br J Ophthalmol 2015; 23: 59-66 [IF 3.036]
Januschowski K, Leers S, Haus A, Szurman P, Seuthe AM, Boden KT. Is trabeculectomy really superior to canaloplasty? Acta Ophthalmol 2016; 94:666-667 [IF 3.032]
Süsskind D, Neuhann I, Hilgers RD, Hagemann U, Szurman P, Bartz-Schmidt KU, Aisenbrey S. Primary vitrectomy for rhegmatogenous retinal detachment in pseudophakic eyes: 20-gauge versus 25-gauge vitrectomy. Acta Ophthalmol. 2016; 94: 824-828 [IF 3.032]
Szurman GB, Januschowski K, Szurman P, Feltgen N, Spitzer B, Pielen A, Rehak M, Spital G, Dimopoulos S, Bevacizumab Study Group Venous Occlusion, Meyer CH. Injection scheme for intravitreal bevacizumab therapy for macular oedema due to central retinal vein occlusion: results of a multicentre study. Acta Ophthalmol 2017; 95: 245-246 [IF 3.032]
Januschowski K, Schnichels S, Hagemann U, Koch V, Hofmann J, Spitzer MS, Bartz-Schmidt KU, Szurman P, Lüke M, Aisenbrey S. Electrophysiological toxicity testing of VEGF Trap-Eye in an isolated perfused vertebrate retina organ culture model. Acta Ophthalmol. 2014: 92: 305-311 [IF 3.032]
Mariacher S, Ebner M, Seuthe AM, Januschowski K, Ivanescu C, Opitz N, Szurman P, Boden KT. Femtosecond laser-assisted cataract surgery: First clinical results with special regard to central corneal thickness, endothelial cell count, and aqueous flare levels. J Cataract Refract Surg 2016; 1151-1146. [IF 3.020]

 

Vollständiges Verzeichnis der Publikationen nach Jahrgang
Jahrgänge

 2021

 2020

 2019

 2018

 2017

 2016

 2015

 2014

 2013

 2012

 2011

 2010

 2009

 2008

 2007

 2006

 2005

 2004

 2003

 2002

 2001

 2000

 1999

 1998

 1997

 1996

 1995

Kontakt

Callcenter:
06897 / 574-1121

E-Mail-Formular

Notfallambulanz (Pforte, außerhalb der Callcenter-Sprechzeiten):
06897 / 574-0

Privatambulanz (Chefarzt-Sekretariat):
06897 / 574-1119

Adresse:
Augenklinik Sulzbach, An der Klinik 10
66280 Sulzbach

Anfahrt

Kontakt

Logo KHERI augenklinik saar

KTQ Zertifikat

Wussten Sie schon?

Unser hohes Maß an Qualität wurde uns als erster Klinik im Saarland offiziell zertifiziert. Das KTQ-Siegel steht für Patientenorientierung, geprüfte Qualität und Sicherheit.